These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7960137)

  • 21. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
    Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
    Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
    Kantele A; Pakkanen SH; Karttunen R; Kantele JM
    PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines.
    Alugupalli KR
    Front Immunol; 2024; 15():1383476. PubMed ID: 38799439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation and immunogenicity-evaluation of typhoid O-specific polysaccharides bio-conjugate vaccines.
    Peng ZH; Pan C; Sun P; Feng EL; Wu J; Zhu L; Peng QZ; Wang HL
    Yi Chuan; 2015 May; 37(5):473-9. PubMed ID: 25998436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.
    Fattom A; Schneerson R; Szu SC; Vann WF; Shiloach J; Karakawa WW; Robbins JB
    Infect Immun; 1990 Jul; 58(7):2367-74. PubMed ID: 2114365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.
    Konadu E; Shiloach J; Bryla DA; Robbins JB; Szu SC
    Infect Immun; 1996 Jul; 64(7):2709-15. PubMed ID: 8698499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
    Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
    J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The need & the issues related to new-generation typhoid conjugate vaccines in India.
    Vashishtha VM; Kalra A
    Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Honda-Okubo Y; Cartee RT; Thanawastien A; Seung Yang J; Killeen KP; Petrovsky N
    Vaccine; 2022 Jul; 40(32):4625-4634. PubMed ID: 35750538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL.
    Schneerson R; Fattom A; Szu SC; Bryla D; Ulrich JT; Rudbach JA; Schiffman G; Robbins JB
    J Immunol; 1991 Oct; 147(7):2136-40. PubMed ID: 1918948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay.
    Ahmadi H; Tabaraie B; Maleknia S; Shapouri R; Nejati M; Pour Mirza Gholi F; Hedayati M; Sadati M; Zahednia S; Sharifat Salmani A
    J Med Microbiol; 2013 Feb; 62(Pt 2):283-286. PubMed ID: 23105026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.
    Tritama E; Riani C; Rudiansyah I; Hidayat A; Kharisnaeni SA; Retnoningrum DS
    Hum Vaccin Immunother; 2018 Jun; 14(6):1524-1529. PubMed ID: 29359991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.
    Thiem VD; Lin FY; Canh DG; Son NH; Anh DD; Mao ND; Chu C; Hunt SW; Robbins JB; Schneerson R; Szu SC
    Clin Vaccine Immunol; 2011 May; 18(5):730-5. PubMed ID: 21411598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes.
    Hitri K; Kuttel MM; De Benedetto G; Lockyer K; Gao F; Hansal P; Rudd TR; Beamish E; Rijpkema S; Ravenscroft N; Bolgiano B
    Vaccine; 2019 Jun; 37(29):3866-3875. PubMed ID: 31160100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.